United States, July 16 -- Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, and Avenue Biosciences, a transatlantic protein engineering company, today jointly announce a research collaboration to combine their synergistic technologies to improve long-term expression of secreted proteins, relevant for treatment of a broad range of diseases.Secreting proteins from cells into surrounding tissue, or into circulation, opens new treatment opportunities beyond classical gene therapy for monogenic disease. Circio's circVec platform drives higher and more durable protein expression. Avenue Biosciences' protein engineering technology improves protein release ("secretion") from c...